WO1995011684A1 - Inhibiteur antagoniste de la croissance des cellules mesenchymateuses - Google Patents
Inhibiteur antagoniste de la croissance des cellules mesenchymateuses Download PDFInfo
- Publication number
- WO1995011684A1 WO1995011684A1 PCT/JP1993/001581 JP9301581W WO9511684A1 WO 1995011684 A1 WO1995011684 A1 WO 1995011684A1 JP 9301581 W JP9301581 W JP 9301581W WO 9511684 A1 WO9511684 A1 WO 9511684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rheumatoid arthritis
- cells
- cell growth
- mesenchymal cell
- inhibitor against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Definitions
- the present invention relates to an anti-proliferative phase of mesenchymal cells and a method for treating collagen disease using the same. More specifically, the present invention relates to a novel therapeutic agent which is particularly useful for inhibiting the binding of C-fos protein, which triggers cell proliferation, to a gene and preventing the onset of rheumatism. It relates to a method of treatment using the method.
- collagen disease which refers to a group of diseases in which inflammation of the connective tissue of the body is the main lesion, has been known as an intractable disease that is difficult to elucidate and treat its cause worldwide.
- this collagen disease includes rheumatoid arthritis, rheumatic fever, polymyositis, scleroderma, and the like.
- RA rheumatoid arthritis
- the treatment is not out of the empirical range, and at present, there is no therapeutic drug with such a significant effect developed. This seems to be partly due to the fact that the current development of therapeutics is not always based on the results of state-of-the-art etiological research.
- the cause of the chronicity of (2) is due to abnormal proliferation of synovial cells in the joint.
- synovial proliferation is thought to be closely related to the increase in substances that stimulate synovial cells (such as site force proteins).
- rheumatoid arthritis begins with a local immune response initiated by an unknown pathogen that reaches the synovium from the blood. Then, macrophages, T cells, B cells, neutrophils, etc., flow into the blood, causing complicated chronic inflammation to develop, and finally, joint destruction.
- Important factors involved in this process include the specific recognition system such as T cells and B cells under the control of the immune memory of the specific response to the antigen, as well as the site power that is widely involved in chronic inflammation.
- mesenchymal cells are not only for rheumatoid arthritis, but also for collagen disease itself.
- the present invention overcomes the limitations of the prior art described above, and provides a new therapeutic agent effective for the treatment of collagen diseases including rheumatoid arthritis and the like, and a therapeutic method using the same.
- the purpose is.
- the present invention solves the above-mentioned problems by increasing the number of mesenchymal cells characterized by containing an AP-1 nucleotide consisting of TGAGTCA or TGACTCA constituting a gene expression promoter.
- An anti-proliferative inhibitor is provided.
- the present invention also provides a method for treating collagen diseases including rheumatoid arthritis, to which the above-mentioned AP-1 nucleotide is administered.
- the present invention is basically intended to prevent the occurrence of pathogenesis such as joint destruction by suppressing synovial mesenchymal cells.
- pathogenesis such as joint destruction by suppressing synovial mesenchymal cells.
- pathogenesis such as joint destruction by suppressing synovial mesenchymal cells.
- the joint lesions in rheumatoid arthritis include T cells, which are the center of the response system responsible for immune memory, and “direct” involvement in joint destruction.
- T cells Two of the synovial mesenchymal cells (Shiozawa et al. Ann. Rheum. Dis. 51: 869, 1992) to be given are basically important. The latter is a major component of pannus and produces site forces such as IL1, IL6, and TNF that are important in synovial lesions of rheumatoid arthritis (Shiozawa et al. Sem. Arthritis Rheum. 1: 267, 19992). No ,. Although they have the ability to grow at first glance like tumors,
- the c-fos gene is expressed in large amounts in the synovium of rheumatoid arthritis.
- the human c-ios gene is continuously expressed in osteoblasts by transfection, the synthesis of type I collagen and mRNA Expression is suppressed (Kuroki, Shiozawa et al. BBRC 182: 1389,
- the present invention has been made based on the finding that the c_fos gene particularly activates mesenchymal cells, and has studied the mechanism of action thereof.
- the c-f0s protein is a gene for the rheumatoid arthritis-onset gene. It is assumed that it acts on the AP-1 site of the mouth motor to regulate gene expression.
- This promoter has the following formula
- the AP-1 site means TGAGTCA shown underlined in the above. Although DNA is double-stranded, only one is read during protein synthesis, and the c-fos protein complex binds to both.
- TGAGTCA or an AP-1 nucleotide consisting of TGACTCA constituting the gene expression promoter as described above is used as an antagonist of mesenchymal cell proliferation.
- AP-1 nucleotides described above may be used in combination with various other additional requirements.
- the thickness of the foot pad was 6 Z 14 cases (43%) in the experimental group, and 12 Z 16 cases (75%) in the control group. Histologically significant inflammatory cell infiltration was observed in 71.4 cases (50%) in the experimental group and 8Z16 cases (50%) in the control group.
- o Injured arthritis there 1 2/1 4 cases in experimental groups (8 6%), 2 Z 1 6 cases in the control group (1 or 3 in which was c, before and after the change of mouse body weight experiments, the experimental group 1 5 1% , Contrast There was no difference between the two groups, 144% in the group.
- administered AP-1 suppressed the expression system such as interleukin-1 acting through the AP-1 site, but not through AP-1 It did not act on the gene expression system, confirming its specificity.
- the administered AP_1 nucleotide significantly suppressed the joint destruction in mouse collagen arthritis.
- the degree of infiltration of inflammatory cells into the local joints did not differ between the two groups, while significant suppression of joint destruction was observed.
- This result indicates that infiltrating inflammatory cells are not necessarily directly involved in joint destruction in arthritis, and that the inflammatory cells are not directly involved in joint destruction in H2-c-fos transgenic mice.
- the present invention enables the treatment of collagen diseases, particularly rheumatoid arthritis, and has great promise for clinical application. It is expected to elucidate the etiological mechanism of rheumatoid arthritis and to apply it to the elucidation of the pathogenesis and treatment of other chronic inflammatory diseases or intractable diseases in which the proliferation of mesenchymal cells is important for the pathological condition.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT93923675T ATE232731T1 (de) | 1993-10-29 | 1993-10-29 | Verwendung der gensequenz eines promotors zur behandlung rheumatischer erkrankungen |
DE69332702T DE69332702T2 (de) | 1993-10-29 | 1993-10-29 | Verwendung der gensequenz eines promotors zur behandlung rheumatischer erkrankungen |
KR1019960702187A KR100306376B1 (ko) | 1993-10-29 | 1993-10-29 | 간엽계세포의증식길항저해제 |
ES93923675T ES2188597T3 (es) | 1993-10-29 | 1993-10-29 | Uso de una secuencia genica promotora para el tratamiento de enfermedades reumaticas. |
AU53452/94A AU683626B2 (en) | 1993-10-29 | 1993-10-29 | Antagonistic inhibitor for the proliferation of mesenchymal cells |
DK93923675T DK0733370T3 (da) | 1993-10-29 | 1993-10-29 | Anvendelse af en genpromotorsekvens til behandling af rheumatiske sygdomme |
EP93923675A EP0733370B1 (en) | 1993-10-29 | 1993-10-29 | Use of a gene promoter sequence for the treatment of rheumatic diseases |
PT93923675T PT733370E (pt) | 1993-10-29 | 1993-10-29 | Utilizacao da sequencia de um promotor genico para o tratamento de doencas reumaticas |
CA002175368A CA2175368C (en) | 1993-10-29 | 1993-10-29 | Proliferation antagonistic inhibitor of mesenchymal cells |
PCT/JP1993/001581 WO1995011684A1 (fr) | 1993-10-29 | 1993-10-29 | Inhibiteur antagoniste de la croissance des cellules mesenchymateuses |
US10/440,256 US7615538B2 (en) | 1993-10-29 | 2003-05-19 | Method for therapy of rheumatoid arthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1993/001581 WO1995011684A1 (fr) | 1993-10-29 | 1993-10-29 | Inhibiteur antagoniste de la croissance des cellules mesenchymateuses |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08637676 A-371-Of-International | 1996-07-11 | ||
US51433900A Continuation-In-Part | 1993-10-29 | 2000-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995011684A1 true WO1995011684A1 (fr) | 1995-05-04 |
Family
ID=14070618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001581 WO1995011684A1 (fr) | 1993-10-29 | 1993-10-29 | Inhibiteur antagoniste de la croissance des cellules mesenchymateuses |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0733370B1 (ja) |
KR (1) | KR100306376B1 (ja) |
AT (1) | ATE232731T1 (ja) |
AU (1) | AU683626B2 (ja) |
CA (1) | CA2175368C (ja) |
DE (1) | DE69332702T2 (ja) |
DK (1) | DK0733370T3 (ja) |
ES (1) | ES2188597T3 (ja) |
PT (1) | PT733370E (ja) |
WO (1) | WO1995011684A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0732929A1 (en) * | 1993-10-29 | 1996-09-25 | Victor J. Dzau | Therapeutic use of cis-element decoys in vivo |
DE29916160U1 (de) | 1999-09-14 | 2000-03-09 | Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath | Modulation der Transkription von Genen in vaskulären Zellen |
US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7615538B2 (en) * | 1993-10-29 | 2009-11-10 | Shunichi Shiozawa | Method for therapy of rheumatoid arthritis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006570A1 (en) * | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011535A1 (en) * | 1990-01-30 | 1991-08-08 | Childrens Hospital Of Los Angeles | Inhibition of transcription by double-stranded oligonucleotides |
JPH06502532A (ja) * | 1990-10-10 | 1994-03-24 | ラ ジョラ キャンサー リサーチ ファウンデーション | 核受容体を用いた転写抑制の方法 |
JPH06509704A (ja) * | 1991-04-18 | 1994-11-02 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 特定dna配列に選択的に結合する蛋白質に対する偽構築体として有用なオリゴデオキシヌクレオチドおよびオリゴヌクレオチド |
WO1993014768A1 (en) * | 1992-01-27 | 1993-08-05 | The Trustees Of The University Of Pennsylvania | Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function |
-
1993
- 1993-10-29 AU AU53452/94A patent/AU683626B2/en not_active Expired
- 1993-10-29 ES ES93923675T patent/ES2188597T3/es not_active Expired - Lifetime
- 1993-10-29 KR KR1019960702187A patent/KR100306376B1/ko not_active IP Right Cessation
- 1993-10-29 DK DK93923675T patent/DK0733370T3/da active
- 1993-10-29 WO PCT/JP1993/001581 patent/WO1995011684A1/ja active IP Right Grant
- 1993-10-29 EP EP93923675A patent/EP0733370B1/en not_active Expired - Lifetime
- 1993-10-29 AT AT93923675T patent/ATE232731T1/de active
- 1993-10-29 DE DE69332702T patent/DE69332702T2/de not_active Expired - Lifetime
- 1993-10-29 CA CA002175368A patent/CA2175368C/en not_active Expired - Lifetime
- 1993-10-29 PT PT93923675T patent/PT733370E/pt unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006570A1 (en) * | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
Non-Patent Citations (2)
Title |
---|
NUCLEIC ACIDS RESEARCH; Vol, 21, (No. 11), p. 2715-21, (1993), T. YOSHIDA et al., "Analysis of Fra-2 Gene Expression". * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 267, (No. 30), p. 21894-21900, (1992), J. ALAM et al., "Distal AP-1 Binding Sites Mediate Basal Level Enhansment and TPA Induction of the Mouse Heme Oxygenase-1 Gene". * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0732929A1 (en) * | 1993-10-29 | 1996-09-25 | Victor J. Dzau | Therapeutic use of cis-element decoys in vivo |
EP0732929A4 (en) * | 1993-10-29 | 2001-11-14 | Victor J Dzau | THERAPEUTIC USE OF CIS ELEMENT TRAPS IN VIVO |
EP1340505A2 (en) * | 1993-10-29 | 2003-09-03 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
EP1350514A2 (en) * | 1993-10-29 | 2003-10-08 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
EP1350514A3 (en) * | 1993-10-29 | 2004-07-07 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
EP1340505A3 (en) * | 1993-10-29 | 2004-07-14 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
US6774118B1 (en) | 1993-10-29 | 2004-08-10 | The Brigham And Women's Hospital, Inc. | Therapeutic use of CIS-element decoys in vivo |
US6821956B2 (en) | 1993-10-29 | 2004-11-23 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
DE29916160U1 (de) | 1999-09-14 | 2000-03-09 | Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath | Modulation der Transkription von Genen in vaskulären Zellen |
US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
US7186556B2 (en) | 1999-09-14 | 2007-03-06 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
Also Published As
Publication number | Publication date |
---|---|
DE69332702D1 (de) | 2003-03-27 |
ATE232731T1 (de) | 2003-03-15 |
CA2175368C (en) | 2004-07-20 |
EP0733370A1 (en) | 1996-09-25 |
EP0733370B1 (en) | 2003-02-19 |
DK0733370T3 (da) | 2003-04-07 |
AU5345294A (en) | 1995-05-22 |
CA2175368A1 (en) | 1995-05-04 |
EP0733370A4 (en) | 1999-12-29 |
ES2188597T3 (es) | 2003-07-01 |
PT733370E (pt) | 2003-07-31 |
AU683626B2 (en) | 1997-11-20 |
KR100306376B1 (ko) | 2001-11-30 |
DE69332702T2 (de) | 2003-10-16 |
KR960705576A (ko) | 1996-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Joosten et al. | Anticytokine treatment of established type II collagen–induced arthritis in DBA/1 mice: a comparative study using anti‐TNFα, anti–IL‐1α/β, and IL‐1Ra | |
JP2018537528A (ja) | Nlrp3遺伝子発現を阻害するための組成物およびその使用 | |
Li et al. | GDF11 antagonizes TNF‐α‐induced inflammation and protects against the development of inflammatory arthritis in mice | |
JP2012505221A (ja) | 高コレステロール血症および高脂血症ならびにそれらに関連する疾患の予防および処置におけるトル様受容体の阻害剤の使用 | |
JP2011148801A (ja) | 疾患を予防および治療するための方法および免疫調節核酸組成物 | |
Segal et al. | Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis | |
AU2009321740B2 (en) | IL-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage | |
Venturini et al. | Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini‐review with a representative case report. | |
US7282490B2 (en) | Osteopontin-related compositions and methods | |
Moor et al. | Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results | |
Yang et al. | Inflammasomes and their roles in arthritic disease pathogenesis | |
Qin et al. | MALT-1 inhibition attenuates the inflammatory response of ankylosing spondylitis by targeting NF-κB activation | |
JP2009540016A (ja) | 疾患を予防および処置するための方法および免疫調節核酸組成物 | |
US20230310409A1 (en) | Treating rheumatoid arthritis | |
EP1206527A1 (en) | Treatment of inflammatory or malignant disease using dnazymes | |
WO1995011684A1 (fr) | Inhibiteur antagoniste de la croissance des cellules mesenchymateuses | |
Ye et al. | The roles of interleukin-18 in collagen-induced arthritis in the BB rat | |
EP1151092A1 (en) | Inhibiting formation of atherosclerotic lesions | |
Hamilton et al. | Advances in the treatment of rheumatoid arthritis: old versus new therapies | |
RU2311456C2 (ru) | Модуляция экспрессии stat-1-зависимых генов | |
Schett et al. | New insights in the mechanism of bone loss in arthritis | |
JP3847351B2 (ja) | 間葉系細胞の増殖拮抗阻害剤 | |
Kuroda et al. | Effects of viral interleukin 10 introduced by in vivo electroporation on arthrogen-induced arthritis in mice. | |
JPH09176038A (ja) | 抗炎症性アンチセンス薬物 | |
EP1545612A1 (en) | Modulation of mesenchymal cells via iga-receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019960702187 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2175368 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993923675 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 637676 Country of ref document: US Date of ref document: 19960711 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993923675 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993923675 Country of ref document: EP |